1. Home
  2. KRMD vs NYXH Comparison

KRMD vs NYXH Comparison

Compare KRMD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

HOLD

Current Price

$4.44

Market Cap

192.5M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.75

Market Cap

161.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRMD
NYXH
Founded
1980
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.5M
161.9M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
KRMD
NYXH
Price
$4.44
$1.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$6.50
$9.33
AVG Volume (30 Days)
153.7K
525.3K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
53.85
N/A
EPS
N/A
N/A
Revenue
$41,127,366.00
N/A
Revenue This Year
$20.32
$213.98
Revenue Next Year
$17.37
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
22.23
N/A
52 Week Low
$2.91
$1.26
52 Week High
$6.61
$8.59

Technical Indicators

Market Signals
Indicator
KRMD
NYXH
Relative Strength Index (RSI) 62.63 39.17
Support Level $3.84 $1.26
Resistance Level $4.68 $3.36
Average True Range (ATR) 0.19 0.12
MACD 0.05 0.07
Stochastic Oscillator 91.67 81.82

Price Performance

Historical Comparison
KRMD
NYXH

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: